KDR and neoplasm: Anlotinib is an oral TKI that targets multiple kinases such as VEGFR2, fibroblast growth factor receptors (FGFR1‐3), PDGFRβ and c‐Kit and can effectively inhibit tumor growth and vasculature [10].